Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT03504488 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors

Start date: May 13, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

NCT ID: NCT03502330 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Start date: April 2018
Phase: Phase 1
Study type: Interventional

This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab. The phase 1 dose escalation portion of the study will enroll patients with advanced solid tumors melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) in 6 cohorts to determine the recommended phase II dose (RP2D) of APX005M. The phase 1b dose expansion portion will study the triple drug combination separately in the three disease cohorts: melanoma, NSCLC, and RCC. Submitted on 3/29/2018; investigational new drug (IND) number is pending and will be added to the record once received.

NCT ID: NCT03496766 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Start date: May 30, 2018
Phase: Phase 2
Study type: Interventional

This Phase II study consists of 2 parts: 1) pre-screening phase and 2) treatment phase. The pre-screening phase will investigate the presence of HRAS mutations in subjects with a histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (SQ-NSCLC). Subjects may participate in the pre-screening phase at initial diagnosis or following prior lines of therapy for SQ-NSCLC. The treatment phase will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with locally advanced squamous non-small cell lung cancer (SQ-NSCLC) with HRAS mutations and for whom there is no curative therapy available.

NCT ID: NCT03490669 Not yet recruiting - Ovarian Cancer Clinical Trials

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Start date: May 1, 2018
Phase: Phase 1
Study type: Interventional

This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with Advanced Solid Tumors. In part 1, multiple dose levels of MSC-1 in patients with Advanced Solid Tumors will be studied to determine the recommended dose for further evaluation of safety and efficacy in Part 2.

NCT ID: NCT03486730 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

BT1718 in Patients With Advanced Solid Tumours.

Start date: January 24, 2018
Phase: Phase 1
Study type: Interventional

This clinical trial is looking at a drug called BT1718 in adult patients with advanced solid tumours. The main aim of the study is to find the maximum dose of BT1718 that can be given safely to patients; learn more about the potential side effects of BT1718 and how they can be treated and also what happens to BT1718 inside the body.

NCT ID: NCT03486119 Recruiting - Clinical trials for Non -Small Cell Lung Cancer

A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients

Start date: February 5, 2018
Phase:
Study type: Observational

The study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-1 blockade and evaluate the dynamics of immune cells in peripheral blood from NSCLC patients during nivolumab treatment. Hypothesis that The ratio of MDSC after 1st or 2nd cycle can predict the response to nivolumab in NSCLC patients earlier than the tumor assessment by imaging scan. The primary objective is to determine whether myeloid-derived suppressor cell (MDSC) ratio after 1st or 2nd cycle of nivolumab can be accurate predictive biomarkers of nivolumab in advanced NSCLC.

NCT ID: NCT03485378 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

ASPIRE-ILD
Start date: June 2018
Phase: N/A
Study type: Interventional

This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.

NCT ID: NCT03485326 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

Start date: April 30, 2018
Phase:
Study type: Observational

This is a multi-center, prospective, non-interventional study. The study will enroll about 1700 Chinese patients diagnosed as NSCLC and treated with osimertinib at least one dose. The objective of this non-interventional study is to monitor the safety profile of osimertinib in Chinese NSCLC patients in real world clinical practice.

NCT ID: NCT03481114 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

REPAINT
Start date: August 28, 2017
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate patient-reported outcomes during and after concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer. Patients will be randomized to a standard 6-week radiotherapy course or a 4-week radiotherapy course using dose-painting based on pre-treatment PET findings.

NCT ID: NCT03481101 Recruiting - Clinical trials for Non Small Cell Lung Cancer

WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC

WHENII
Start date: February 28, 2018
Phase: N/A
Study type: Interventional

Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.